EVENTS:   Best Equity Short Ideas Conference Call 12 - Zach Shannon/Corto Capital Advisors & Craig Huber/Huber Research Partners & Thomas Beevers /Forensic Alpha & Ed Steele/Iron Blue Financials & Bill Campbell/Paragon Intel - 12 Nov 25   Will AI Deflate the World? Macro Lessons from Three Industrial Revolutions and China - Manoj Pradhan/Talking Heads Macro - 13 Nov 25     ROADSHOWS: Forest Products Sector Equity and Commodity Research With Expertise in Distressed Debt - Kevin Mason /ERA Research   •   London   12 - 14 Nov 25       Buyside to Buyside Forum and Expert Calls across TMT, Consumer, Healthcare and Fintech - Andrew Peters /Revelare Partners   •   London   17 - 19 Nov 25       Fundamental US Healthcare Short Ideas - Dr Elliot Favus /Favus Institutional Research   •   London   17 - 19 Nov 25      

Fortnightly Publication Highlighting Latest Insights From IRF Providers

Company Research

Dr Martens (DOCS LN) UK

Consumer Discretionary

Pernas Research

No permanent impairment to the brand - DOCS has experienced a recent revenue decline driven by several short-term operational and inventory mishaps (now fixed) along with general cyclical challenges in the footwear category. Analysts at Pernas Research believe DOCS has an enduring appeal across genders, regions, cultures and socio-economics. They also argue that the market is currently discounting several growth opportunities. Pernas (conservatively) estimates FY25 will see a return to 1bn in revenue with an after-tax FCF margin of 9%. Revenue will then grow by 4-7% over the next 4-5 years with gradual increases in FCF margin. Their TP offers 60%+ upside.

Edition: 183

- 05 April, 2024